WASHINGTON, June 10 (Xinhua) -- A key panel of the U.S. Food and Drug Administration (FDA) met on Thursday to discuss the potential use of COVID-19 vaccines in children under 12.
The FDA's Vaccines and Related Biological Products Advisory Committee met in an open session to discuss data needed to support authorization and/or licensure of COVID-19 vaccines for use in pediatric populations, according to the FDA.
The meeting came on the same day that Moderna said it has applied for authorization from the FDA to expand the emergency use of its COVID-19 vaccine in adolescents ages 12 to 17. The vaccine was authorized for adults last December.
If authorized, Moderna vaccine will be the second one authorized for use in children aged 12 to 17 years old in the United States.
The FDA approved the emergency use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12 to 15 on May 10. Enditem
